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Abstract (Word count: 250)
Background and aims
Biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis
(PSC) have not been firmly established. Enhanced Liver Fibrosis (ELF) test was
previously reported to predict outcome in PSC. The aim of this study was to validate
the prognostic utility of ELF test in an independent, multicenter, retrospective PSC
study population.
Methods
We collected serum samples from PSC patients from seven countries. We estimated
rates of transplant-free survival by the Kaplan–Meier method, used Cox proportional
hazards regression to explore the association between ELF test and clinical outcome
and determined prognostic performance of ELF test by computing the area under the
receiver operating characteristic (AUC-ROC) curve.
Results
The final analysis included 534 PSC patients, out of which 324 (61%) were male.
Features of autoimmune hepatitis or concomitant inflammatory bowel disease
affected 44 (8%) and 379 (71%), respectively. ELF test levels were higher in patients
reaching the combined endpoint liver transplantation or death (median 10.9
[interquartile range (IQR) 9.8-12.1]) compared to those censored (8.8 [IQR 8.0-
9.8]);p<0.001. ELF test expressed as mild, moderate and severe fibrosis was
significantly associated with the risk of reaching the endpoint (p<0.001). ELF test was
demonstrated to independently predict clinical outcome (Hazard ratio 1.31; 95%
confidence interval [1.05-1.65];p=0.018), and enabled good discrimination between
PSC patients with and without endpoint (AUC-ROC 0.79).
Conclusion
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Our data validates the predictive utility of ELF test for clinical outcomes in PSC. The
clinical utility of biomarkers for fibrosis in patients with PSC should be assessed in
prospective patient cohorts.
Key Points (4 bullet points; max 100 words)
 Primary sclerosing cholangitis (PSC) is a progressive biliary disease lacking
medical treatment with currently no established tools to predict prognosis in
the individual patient. The lack of biomarkers validated as surrogate endpoints
is an important obstacle to the development of therapy.
 The Enhanced Liver Fibrosis (ELF®) test was previously reported to predict
clinical outcome in two Norwegian PSC cohorts independently of clinical risk
scores.
 Our data confirm, in a large, international, multicenter cohort, that ELF test
predicts prognosis in PSC and may be used for risk stratification in clinical
follow-up.




Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease of
unknown etiology resulting from the development of fibrotic strictures throughout the
biliary tree. Eventually most patients develop end-stage liver failure.[1] In the
absence of medical treatment options the only curative treatment modality is liver
transplantation,[2] and PSC is the number one indication of liver transplantation
within the spectrum of autoimmune and cholestatic liver disease.[3]
There is an unmet need for medical therapeutic options in the management of
PSC patients. However, the development of new treatment strategies is severely
hampered by the slowly progressive nature and low event rate of this disease, which
results in difficulties to demonstrate treatment effects in clinical trials.[4] New
developments in the design of clinical trials in PSC show a shift from measuring
treatment effect by the traditionally used ‘solid endpoints’ such as death and liver
transplantation, to an effort to establish and implement easier attainable ‘surrogate
endpoints’ that have been proven to be predictive of clinical outcome.[4]
Liver fibrosis is a well-established predictor of outcome in PSC – exemplified
by the implementation of liver histology and liver elastography in several prognostic
models for PSC.[5–9] Over recent years, non-invasive methods to measure liver
fibrosis have gained interest, including the use of serum biomarkers. The Enhanced
Liver Fibrosis (ELF) test is a promising panel, incorporating three direct serum
markers of fibrosis in an algorithm: hyaluronic acid, tissue inhibitor of
metalloproteinases-1 (TIMP-1), and amino-terminal pro-peptide of type III pro-
collagen (PIIINP).[10,11] The ELF test was shown to accurately predict significant
liver fibrosis and was furthermore able to predict clinical outcome in several
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independent populations and in patients with various etiologies of chronic liver
disease.[12–16]
Recently, the prognostic value of the ELF test in PSC was assessed in a large
single center study from Norway including two independent PSC cohorts.[17] It was
demonstrated that ELF test consistently predicted liver transplant-free survival in
PSC patients independently of other risk factors or risk scores.[17] In the present
study, we aimed to validate the prognostic value of the ELF test in a large, multi-
center PSC cohort.
PATIENTS AND METHODS
Study design, patient and tissue requirements
For this multicenter cohort study, PSC patients from seven centers in six European
countries and Canada were included: Helsinki University Hospital, Helsinki, Finland;
Medical University of Warsaw, Warsaw, Poland; University of Calgary, Calgary,
Canada; Hôpital Saint Antoine, Paris, France; Hospital Clínic, Barcelona, Spain;
Humanitas Clinical and Research Center, Rozzano, Italy, and the Academic Medical
Center, Amsterdam, the Netherlands. PSC diagnosis was established according to
the EASL clinical practice guidelines.[18] A diagnosis of PSC with features of
autoimmune hepatitis (AIH) was made in keeping with expertise of the contributing
center. The individual centers received ethic approval at the national level and all
patients provided written, informed consent.
Clinical data had previously been collected in the context of the international
immunochip-subphenotyping project, conducted by the International PSC Study
Group (Alberts R et al. Genotype-phenotype analysis across 130 422 genetic
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variants identifies RSPO3 as the first genome-wide significant modifier gene in
primary sclerosing cholangitis. ECCO 2016). Where missing, additional clinical and
laboratory data as well as data on liver biochemistry at time of the ELF test sample
withdrawal (+/- 1 month) were retrospectively retrieved from patient files by the
participating centers. We collected the following clinical data: gender, date of PSC
diagnosis, PSC phenotype, concomitant inflammatory bowel disease (IBD), type of
IBD and date of IBD diagnosis, autoimmune hepatitis overlap syndrome, the
occurrence of hepatobiliary malignancy, liver transplantation and death or date of last
follow-up. IBD diagnosis was based on findings at colonoscopy and histology.
Patients with a diagnosis of small duct PSC and patients for whom successful serum
analysis of ELF test was not achieved, were excluded from the study.
Deep frozen serum samples were collected from 577 PSC patients. For
determination of the ELF test, serum samples were analyzed by the commercially
available ELF®Test (Siemens Medical Solutions Diagnostics Inc., Tarrytown, NY,
USA). The assays were performed using the Siemens ELF®Test kits and an ADVIA
Centaur XP analyzer (Siemens Medical Solutions Diagnostics Inc., Tarrytown, NY,
USA).
Statistical Analysis
Patient characteristics and laboratory values were expressed as median and
interquartile range when having a skewed distribution, dichotomous variables were
expressed as percentage (%) of the cohort. Since reference values of biochemical
variables differed slightly in between centers according to local instrumentation and
kit, all biochemical variables were expressed using a ratio of times upper or lower
limit of normal. Biochemical values showing a skewed distribution were transformed
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using natural logarithmic transformation. Continuous variables were tested for normal
distribution, and for comparison between groups the Student’s t-test or the Mann-
Whitney U test was applied, as appropriate.
Time of PSC diagnosis was defined by the first pathological cholangiogram. A
composite endpoint composed by all-cause death and liver transplantation was
defined.[17] Survival time was calculated as the interval between the date of serum
withdrawal for the ELF test and the date of reaching the first endpoint, or, in case no
endpoint was reached, date of last follow-up.
Rates of transplant-free survival were estimated for three groups of fibrosis
severity: mild, moderate and severe fibrosis defined as ELF test level <7.7, ≥7.7 to 
<9.8, and ≥9.8, respectively, as recommended by the manufacturer; crude risk was 
compared using log-rank test. Due to the small number of patients with a follow-up
longer than 60 months (n=37 out of 516), survival curves were truncated at 60
months.
Univariable Cox proportional hazards model was used to assess the potential
association of all clinical and biochemical variables with the occurrence of the
endpoint. Factors that were significantly associated (P<0.05) with outcome in the
univariable analysis were entered into the multivariable model. Using stepwise
forward multivariable Cox regression analysis, the independent prognostic value of
ELF test was assessed. The criterion for retaining predictors was a p-value <0.05.
The proportionality during follow-up for risk prediction with the ELF test as a
continuous variable was found acceptable for all assays and cohorts as tested by the
cox.zph function in R.
The prognostic performance of the ELF test was determined by computing the
area under the receiver operating characteristic (ROC) curve. The optimal threshold
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to distinguish patients that experience an endpoint from those that do not, was
calculated by Youden’s index – the maximum total sensitivity and specificity.
Correlation between the ELF test and the prognostic index as calculated by
the novel Amsterdam-Oxford prognostic model including PSC type, age at PSC
diagnosis, albumin, platelets, aspartate aminotransferase, alkaline phosphatase and
bilirubin,[19] was assessed by Spearman’s rank correlation test. To assess the
additive value of ELF over routine biomarkers as used in the Amsterdam-Oxford
model the prediction increment of the ELF test when added as a predictor to this
prognostic model for PSC was calculated by the category-free net reclassification
index.
Statistical analyses were performed using SPSS version 22.0 software (SPSS,
Chicago, IL); calculation of the net reclassification index and testing for the
proportional hazards assumptions were performed in R (R Foundation for Statistical
Computing, Vienna, Austria). p<0.05 was considered statistically significant.
RESULTS
Patient characteristics
Serum samples of 577 PSC patients were received from the participating centers. A
total of 17 samples were excluded because of insufficient serum volumes for
adequate ELF® test assessment, and five samples were excluded following analysis
due to inability to calculate the ELF test because of undetectable (<0.50 ng/mL) or
high (out of range despite 1:10 dilution) PIIINP levels in repeated analyses (n=3 and
1, respectively), or (for one patient) widely discrepant results from duplicate samples
(hyaluronic acid 42.02 vs 11.79, PIIINP 21.85 vs 2.94 and TIMP1 331.9 vs 58.2). In
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addition, 21 patients diagnosed with small duct PSC were excluded. The final number
of patients included in the statistical analysis was 534.
The median age at PSC diagnosis was 34 years (IQR 25-45), and 379 (71%)
patients suffered from concurrent IBD, out of which 289 (54% of the total study
population) were classified as ulcerative colitis. The median disease duration at time
of serum withdrawal for ELF test analysis was 57 months (IQR 28-111). An overview
of baseline characteristics and laboratory values at time of ELF test sample
withdrawal is provided in Table 1.
Differentiation of PSC phenotype by ELF test score
The ELF test was higher in patients reaching an endpoint than in those censored,
with medians of 10.9 (IQR 9.8-12.1) and 8.8 (IQR 8.0-9.8), respectively; p<0.001.
The median ELF test did not differ between patients with and without inflammatory
bowel disease (median 9.1 [IQR 8.2-10.5] and 9.2 [IQR 8.2-10.4], respectively;
p=0.936, nor between patients with and without colorectal carcinoma (n=14), median
9.3 [IQR 8.6-11.0] and 9.1 [IQR 8.2-10.5], respectively; p=0.264)
A total of 19 (4%) patients developed hepatobiliary malignancies; 3 gallbladder
carcinomas, 2 hepatocellular carcinomas and 15 cholangiocarcinomas. The ELF test
was significantly higher in the 15 CCA patients compared with non CCA patients,
median 10.7 [IQR 9.0-11.3] and 9.1 [IQR 8.2-10.4], respectively; p=0.024. Ten
patients developed their cholangiocarcinoma after serum withdrawal for ELF test,
with a median interval of 14 months [IQR 11-24]. This subgroup of patients with
cholangiocarcinoma also had a significantly higher ELF test than patients without
cholangiocarcinoma, median 10.7 [IQR 9.3-11.4] and 9.1 [IQR 8.2-10.4], respectively;
p=0.035.
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Prognostic performance of the ELF test
The manufacturer of the ELF test defines three groups of fibrosis severity based on
ELF test scores, i.e. none to mild, moderate, and severe (ELF score <7.7, ≥7.7 to 
<9.8 and ≥9.8, respectively). There was a significant association between the ELF 
test subdivided into three groups based on these definitions (N=81 mild, 257
moderate and 178 severe fibrosis, respectively), and the risk of reaching the clinical
composite endpoint all cause death and liver transplantation, p<0.001 (Figure 1).
Additional Kaplan-Meier survival analysis when applying the composite endpoint PSC
related death and liver transplantation showed a comparable result. (Supplementary
Figure 1)
When re-classifying PSC patients in low-risk and high risk groups based on
the cut-off of ≥9.8 for severe fibrosis, there were 178 (34%) high risk and 338 (66%) 
low risk patients and PSC patients. There were significantly more endpoints in the
high compared to the low risk group (67 [37.6%] vs 23 [6.8%]; odds ratio (OR) 6.72
[95%CI 4.14-10.90]), and this difference persisted if patients with hepatobiliary
malignancy were excluded (n=58 vs 21 endpoints, OR 8.13 [4.71-14.03]). The risk of
liver transplantation alone was also higher in the high risk compared to low risk group
(n=54 vs 19, OR 5.85 (95%CI 3.47-9.86). The high risk group had longer median
PSC duration at ELF test withdrawal compared to the low risk group, i.e. 76
[interquartile range, (IQR) 30-121] and 51 [IQR 28-103] months, respectively;
p=0.039).
The ELF test had a good discriminative ability to distinguish patients that reach
an endpoint from those that do not, with an area under the curve of 0.796 (95% CI
0.746-0.846) p<0.001 (Figure 2). The optimal threshold of the ELF test to
discriminate between patients that do, and do not reach an endpoint was 9.85
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(sensitivity 0.74 [0.64, 0.83], specificity 0.75 [0.71, 0.79], Youden’s index: 0.50).
Applying the previously identified cut-off levels for ELF test in PSC of 11.1 yielded
increased specificity at the cost of reduced sensitivity (sensitivity 0.43 for both,
specificity 0.89 and 0.90, respectively).
Clinical and biochemical prognostic indicators of transplant-free survival
Univariable Cox regression analysis showed a significant association between
transplant-free survival and the following variables: sex, aspartate aminotransferase,
alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin, international
normalized ratio, platelet count, AST to platelet ratio index (APRI), the prognostic
index (defined in Methods), and the ELF test (Table 2). Subsequent multivariable
analysis demonstrated an independent prognostic value of ELF test (hazard ratio
(HR) 1.31 [95% CI 1.05-1.65], p=0.018; Table 3). In addition to ELF test, total
bilirubin and albumin remained independently associated with outcome in
multivariable analysis.
There was a significant correlation between ELF test and the prognostic index of the
Amsterdam-Oxford prognostic model [19] with a correlation coefficient of 0.537,
p<0.001. The net reclassification index (NRI) of adding ELF test to this prognostic
index was highly significant, when ELF test was added as a continuous variable or a




This study confirms the prognostic value of ELF test in the prediction of clinical
outcome in PSC, in a large, well characterized, multicenter PSC cohort. We found
that the ELF test was a strong predictor of clinical outcome as defined by liver
transplantation or death independent of other clinical and laboratory variables
associated with outcome. One unit increase in the ELF test was associated with a
1.31-fold increased risk of death or liver transplantation.
By subdividing ELF test results into three groups of fibrosis severity based on
cut-off levels provided by the manufacturer, we showed that patients with PSC can
be stratified into low, intermediate and high risk groups for the composite endpoint of
death or liver transplantation. Although the difference between these three groups
was statistically significant, when comparing the Kaplan-Meier curves of the present
study with the original results, a diminished ability to distinguish mild from moderate
disease was suggested.[17] This may in part be due to the use of thresholds
proposed by the manufacturer, that were not originally developed to differentiate mild,
moderate and severe disease in a biliary disease with a porto-portal fibrosis pattern
like PSC. However, the manufacturer’s optimal cut-off to discriminate between
patients with and without severe fibrosis (9.8) was similar to the optimal cut-off value
to discriminate between patients that do and do not reach an endpoint as estimated
by the Youden’s index in our study population (9.85), therefore this seems to be a
robust cut-off level to identify high-risk patients. Previously, higher optimal cut-off
values for ELF of 11.1 and 11.2 were identified in two PSC populations;[17]; this
yielded increased specificity at the cost of reduced sensitivity when applied to the
present study population. Further studies in larger patient panels should search to
define PSC-specific cut-off levels that might also robustly identify a low-risk group.
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We report increased ELF test in patients diagnosed with cholangiocarcinoma
(n=15) in line with previous results.[17] The ELF test was increased also in the
subgroup (n=10) of patients who developed cholangiocarcinoma after serum
withdrawal for ELF test analysis. However, the small numbers warrant caution. The
present data do not allow conclusions regarding whether the association between
increased ELF test and CCA in PSC is a result of more advanced disease in these
patients or is explained by the “desmoplastic” and “scirrhous” type of CCA often
found in PSC, showing an excessive fibrotic response in the surrounding tissue,
which may be captured by ELF test.[20,21] Dedicated analyses seem warranted to
further explore the association between ELF test and cholangiocarcinoma.
Regardless, the association of ELF test with CCA does not perturb the significance of
the ELF test as a risk indicator for clinical outcome. Additional analyses excluding
patients with CCA showed similar results (data not shown).
Traditionally, liver biopsy has been considered the reference standard to stage
the degree of liver fibrosis. The role of histology in the clinical management of PSC is
not firmly established. Histologic assessment in PSC can be informative for
assessment of comorbidities, and to estimate prognosis.[22–24] On the other hand,
the usefulness of liver biopsy is limited by the risk of complications for the patient,
sampling error due to a patchy disease distribution, and intra- and inter-observer
variability.[25] Therefore, measurement of liver fibrosis through liver histology is
increasingly replaced by non-invasive modalities in the most prevalent chronic liver
diseases.[26] In PSC, however, there is no consensus yet concerning which of these
techniques should be preferred.
The development of new non-invasive techniques to measure fibrosis, can be
subdivided into two different approaches.[27] First, a ‘biological approach’, based on
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serum biomarkers that represent serum levels of products arising from fibrogenesis
and matrix turnover, as a derivate of degree of fibrosis.[27] Secondly, a ‘physiological
approach’, assessing liver stiffness as a proxy for the degree of scarring of the liver
using imaging techniques such as vibration controlled transient elastography or
magnetic resonance electrography.[27] Measurement of serum biomarkers has the
advantage of being easily applicable, inter-laboratory reproducible and generally
available. Furthermore, serum biomarkers are not influenced by operator experience,
food intake, congestion or obesity.[28–30]
In addition to the ELF test, several other established biomarkers of fibrosis
have been used in other liver diseases, including the AST to platelet ratio index
(APRI)[31], Fibrosis-4-score (an algorithm including age, AST, platelet count and
ALT)[32], and FibroTest (an algorithm including age, Alpha-2-macroglobulin,
Haptoglobin, Apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and
ALT).[33] The diagnostic performance of these biomarkers along with ELF test and
liver histology has been assessed in a PSC patient population that were included in a
randomized trial of simtuzumab.[34] They showed that ELF test could accurately
diagnose advanced fibrosis and cirrhosis with a sensitivity of 97% and 79%, and a
specificity of 9% and 64%, respectively whereas the main value of FibroTest
(sensitivity 58% and 58; specificity 81% and 91%, respectively), APRI (sensitivity
17% and 38%; specificity 95% and 97%, respectively) and FIB-4 (sensitivity 44% and
26%; specificity 78% and 99%, respectively) was in excluding advanced fibrosis and
cirrhosis.[34] These results corroborate previous findings showing that baseline APRI
and FIB-4 did not identify patients with higher risk of developing liver related events
while ELF test did.[16] Our data from a large, international, multicenter cohort confirm
previous findings showing surplus value of ELF test as prognosticator in PSC, when
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compared with other biomarkers of fibrosis, but validation of the ELF test in a
prospective cohort is an important next step before general implementation in clinical
practice can be advocated.[16] Given the discrepant results regarding the ability of
ELF to segregate a specific low-risk group in need of less vigilant follow-up, further
investigations regarding PSC-specific optimal cut-off values is also needed to
establish the optimal clinical management of this group.
In accordance with the previous study [17], we used the composite endpoint
all-cause death and liver transplantation for time-to event analyses. The majority of
patients died of PSC related causes, and large differences between the use of all-
cause death or more specifically PSC related death in this composite endpoint were
not expected. Indeed, Kaplan-Meier survival analysis assessing the association
between the ELF test and the composite endpoint PSC related death and liver
transplantation showed a similar result.
The most widely used prognostic model in PSC research is the Mayo Risk
model. We could not compare nor assess the value of ELF test as an adjunct to the
Mayo risk score because of lack of reliable data on variceal bleeding due to the
retrospective nature of our study. The Mayo risk score, however, failed to predict
adverse outcomes in high-dose ursodeoxycholic acid studies and has not been
validated for individual prognostication. Recently, the novel Amsterdam-Oxford
prognostic model for PSC was presented which was validated in an external PSC
cohort, and is also applicable in early stage disease.[19] The ELF test showed a
moderate correlation with the prognostic index of this model (including the variables
PSC type, age at PSC diagnosis, albumin, platelets, aspartate aminotransferase,
alkaline phosphatase and bilirubin), and calculation of the net reclassification index
showed a significantly increased precision of predicting survival when adding ELF
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test results. These findings suggest that ELF test has an independent prognostic
value in addition to current routine biomarkers, and that the combination of the ELF
test and clinically derived prognostic models in PSC might yield increased prognostic
power, and such composite models warrant further research. Furthermore, it would
be interesting to explore whether compound assessments combining ELF test with
ultrasound- or MR-based liver stiffness measurements and perhaps also clinical
scores, could provide incremental prognostic information.
This study was subject to some limitations. Firstly, in the absence of data on
histological stage, correction for biopsy determined stage of fibrosis in the
multivariable analysis was not possible. Secondly, assessment of the dynamics of the
ELF test over the disease course was not feasible because of the cross-sectional
design of this study. Whether the ELF test reflects merely fibrosis stage or also
disease intensity has not been firmly established. The original paper on the
development of the ELF test describes excellent correlation between ELF test and
degree of fibrosis, but only moderate correlation with histological grade, suggesting
that it is mostly a stage marker.[10] The three basic components of the ELF test
represent various elements of fibrogenesis and matrix turnover (PIIINP reflects both
formation and degradation of pro-collagen III, TIMP1 regulates extracellular matrix
degradation and HA has various roles in wound healing); thus, ELF test is not a
clear-cut fibrosis formation marker. Exploring the dynamics of ELF test results over
time, as well as its ability to measure treatment effect in terms of fibrosis regression is
warranted to establish the ELF test’s applicability in clinical practice and its
usefulness to function as a potential surrogate endpoint in PSC.
In conclusion, we confirm the prognostic value of the ELF test and its ability to
stratify risk of poor outcome in PSC. The clinical utility of the ELF test should be
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further investigated in prospective cohorts. Studies exploring refinements of the
components of the ELF test or compound assessments combining the ELF test with
clinical scores and imaging aiming at incremental prognostic information, might
contribute to improved prognostication. In an era with a considerable clinical need to
identify surrogate markers of liver fibrosis and prognosis to measure treatment effect
in clinical trials for PSC, the ELF test is a promising candidate and investigations
regarding this aspect should be integrated in clinical trials.
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FIGURE LEGENDS
Figure 1. Prediction of transplant-free survival by the ELF test, patients divided
into groups of mild, moderate and severe fibrosis based on ELF levels using
Siemens’ cutoffs.
The figure shows Kaplan-Meier curves of time to transplantation or death for PSC
patients (n=516) stratified into groups of mild, moderate and severe fibrosis defined
as ELF <7.7, ≥7.7 to <9.8, and ≥9.8, respectively, as recommended by the 
manufacturer; illustrating shorter survival in patients in the group with severe fibrosis
as defined by the ELF test compared to patients with intermediate and low ELF
levels.
ELF test, enhanced liver fibrosis test; PSC, primary sclerosing cholangitis.
Figure 2 Prognostic performance of the ELF test.
The prognostic performance of the ELF test was assessed by analysis of the area
under the curve of the receiver operator characteristics curve (AUC-ROC). The ELF
test distinguished patients that reached liver transplantation or death from those that
did not with an area under the curve of 0.796 (95% CI 0.746-0.846), p<0.001,
demonstrating a good discriminatory ability. The optimal threshold of the ELF test to
discriminate between patients that did, and did not reach an endpoint was 9.85
(sensitivity 0.74, specificity 0.75).
AUC-ROC, area under the curve of the receiver operator characteristics curve; ELF
test, enhanced liver fibrosis test; PSC, primary sclerosing cholangitis.
Table 1. Patient characteristics
PSC = primary sclerosing cholangitis; IQR = inter quartile range; AIH = autoimmune hepatitis;
xULN = times upper limit of normal; xLLN = times lower limit; AST = aspartate aminotransferase; ALT
= alanine aminotransferase; ALP = alkaline phosphatase; INR =International normalized ratio; APRI =
AST to platelet ratio index; PI = prognostic index; ELF = enhanced liver fibrosis
* Data available for: AST n= 338, ALT n= 351, ALP n=362, total bilirubin n=339, albumin n=302 INR n =
257, platelet count n=331, creatinine n = 299, APRI n =304, PI = 270; Follow up time from ELF
withdrawal = 516
N 534
Male [n (%)] 324 (61)
Age at diagnosis PSC (years) [median (IQR)] 34 (25-45)
AIH overlap [n (%)] 44 (8)
Inflammatory bowel disease [n (%)] 379 (71)
Ulcerative colitis [n (%)] 289 (54)
Crohn’s disease [n (%)] 63 (12)
Unspecified [n (%)] 27 (5)
Disease duration at ELF withdrawal (months) [median (IQR)] 57 (28-111)
Follow up time from ELF withdrawal (months) [median (IQR)] 23 (5-39)
Death [n (%)] 24 (5)
PSC related death [n (%)] 15 (3)
Liver transplantation [n (%)] 79 (15)
Laboratory values at time of ELF withdrawal
AST xULN, [median (IQR)] 1.04 (0.69-2.05)
ALT xULN, [median (IQR)] 1.15 (0.66-2.26)
ALP xULN, [median (IQR)] 1.35 (0.81-2.52)
Total bilirubin xULN [median (IQR)] 1.23 (0.59-2.73)
Albumin xLLN [median (IQR)] 1.14 (1.04-1.24)
INR [median (IQR)] 1.00 (1.00-1.10)
Platelet count xLLN [median (IQR)] 1.57 (1.21-2.01)
Creatinine xULN [median (IQR)] 0.65 (0.57-0.76)
APRI [median (IQR)] 0.44 (0.28-1.12)
PI Amsterdam=Oxford model PSC [median (IQR)] 1.68 (1.34-2.28)
ELF test [median (IQR)] 9.11 (8.19-10.48)




HR (95% CI) p-value
Sex 534 0.53 (0.33, 0.84) 0.007
Age at PSC diagnosis 534 0.99 (0.98, 1.01) 0.301
Co-existing IBD Y_N 534 1.34 (0.83, 2.17) 0.226
Co-existing IBD type 534 0.99 (0.77, 1.29) 0.956
Disease duration at ELF
withdrawal (months)
516 1.00 (1.00, 1.00) 0.896
Auto-immune hepatitis overlap 534 0.79 (0.34, 1.80) 0.570
Center of inclusion 534 1.12 (0.99, 1.26) 0.066
AST 338 3.19 (2.24, 4.54) <0.005
ALT 351 2.18 (1.61, 2.96) <0.005
ALP 362 2.92 (2.03, 4.18) <0.005
Total bilirubin 339 4.28 (2.81, 6.53) <0.005
Albumin 302 0.11 (0.04, 0.28) <0.005
International normalized ratio 257 4.08 (1.99, 8.38) <0.005
Platelet count 331 0.40 (0.25, 0.63) <0.005
Creatinine 299 0.37 (0.05, 2.51) 0.306
APRI 304 1.45 (1.27, 1.65) <0.005
PI Amsterdam-Oxford model 270 2.53 (1.83, 3.50) <0.005
HA 534 1.001 (1.00, 1.00) <0.005
PIIINP 534 1.04 (1.03, 1.05) <0.005
TIMP1 534 1.002 (1.00, 1.00) <0.005
ELF test 534 1.77 (1.58-1.99) <0.005
PSC = primary sclerosing cholangitis; IQR = inter quartile range; AIH = autoimmune hepatitis;
mm = millimeter; AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP
= alkaline phosphatase; INR =International normalized ratio; APRI = AST to platelet ratio index; PI =
prognostic index; ELF = enhanced liver fibrosis; HR = Hazard ratio; CI = confidence interval.
AST, ALT ALP and total bilirubin were transformed by the natural logarithm prior to regression
analyses due to a right-skewed distribution.
Univariable Cox analyses; n=516 patients with follow-up.
Table 3. Multivariable Cox regression analysis, assessing independent predictors of transplant-
free survival in PSC patients
Multivariable analysis
HR (95% CI) p-value
Total bilirubin 3.44 (1.79-6.63) 0.000
Albumin 0.12 (0.03-0.50) 0.003
ELF test 1.31 (1.05-1.65) 0.018
ELF = enhanced liver fibrosis ; HR = Hazard ratio; CI = confidence Interval.
Multivariable Cox analysis; n=516 patients with follow-up.
Figure 1. Prediction of transplant-free survival by the ELF test, patients divided into groups of
mild, moderate and severe fibrosis based on ELF levels using Siemens’ cutoffs.
Kaplan Meier Curves includes n=516 patients with follow-up.
Figure 2 Receiver operator curve, ELF test.
Supplementary Figure 1. Prediction of transplant-free survival by the ELF test, patients divided
into groups of mild, moderate and severe fibrosis based on ELF levels using Siemens’ cutoffs.
Endpoint PSC related death and liver transplantation;
Kaplan Meier Curves includes n=516 patients with follow-up.
